Marker antibodies in scleroderma and polymyositis: clinical associations

Sera of 34 patients with progressive systemic sclerosis and of 11 patients with polymyositis/dermatomyositis (PM/DM) were analyzed by the immunoblotting technique for the presence of marker antibodies. The presence of anti-centromere, anti-Topoisomerase-I (anti-Topo-I) and anti-Jo-1 antibodies was f...

Full description

Saved in:
Bibliographic Details
Published in:Clinical rheumatology 1989-06, Vol.8 (2), p.231-237
Main Authors: de Rooij, D J, Van de Putte, L B, Habets, W J, Van Venrooij, W J
Format: Article
Language:English
Subjects:
Antibody Specificity
Autoantibodies - analysis
Centromere - immunology
Dermatomyositis - immunology
DNA Topoisomerases, Type I - immunology
Humans
Immunoblotting
Myositis - immunology
Scleroderma, Systemic - classification
Scleroderma, Systemic - immunology
Syndrome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Sera of 34 patients with progressive systemic sclerosis and of 11 patients with polymyositis/dermatomyositis (PM/DM) were analyzed by the immunoblotting technique for the presence of marker antibodies. The presence of anti-centromere, anti-Topoisomerase-I (anti-Topo-I) and anti-Jo-1 antibodies was found to be highly specific for the CREST syndrome, diffuse scleroderma and PM/DM, respectively, but only of limited sensitivity (78, 44 and 45%, respectively). Anti-Topo-I positive diffuse scleroderma patients had a more severe disease (digital pitting scars and renal insufficiency) than anti-Topo-I negative diffuse scleroderma patients. Anti-Jo-1 was associated with interstitial lung disease. Longitudinal studies showed a constant antibody pattern. Our results confirm the clinical usefulness of these marker antibodies.
ISSN:0770-3198
1434-9949
DOI:10.1007/BF02030079